IP Library › Granted Patent US 7,563,278
Granted Patent B2
US 7,563,278 · App. 11/344,870 · Granted Jul 21, 2009

Drug-eluting intravascular prostheses and methods of use

Assignee: Multi-Gene Vascular Systems Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,563,278
App. No.
11/344,870
Granted
Jul 21, 2009
Kind
B2
Abstract

The present invention provides intravascular prostheses and methods of production and use. An implantable device for treating a vascular disease or disorder includes an intravascular prosthesis containing an inhibitor of smooth muscle cell proliferation and a growth factor. The device can be coated with a biodegradable drug-eluting polymer that is impregnated with the inhibitor of smooth muscle cell proliferation and the growth factor. The device is useful for treating or preventing a vascular disease or disorder such as restenosis, by simultaneously inhibiting vessel blockage and enhancing recovery of the vessel wall following an intravascular intervention.

Claims (7)

1. An implantable device for treating a vascular disease or disorder comprising an intravascular prosthesis, wherein said device is coated with a biodegradable drug-eluting polymer that is impregnated with an inhibitor of smooth muscle cell proliferation and a growth factor for enhancing endothelial cell proliferation, wherein said inhibitor of smooth muscle cell proliferation is fibulin-5 polypeptide or a nucleic acid encoding fibulin-5 polypeptide, and wherein said growth factor for enhancing endothelial cell proliferation is VEGF polypeptide or a nucleic acid encoding VEGF polypeptide.

2. The device of claim 1 , wherein the intravascular prosthesis is a stent.

3. The device of claim 1 , wherein the vascular disease is restenosis.

4. The device of claim 1 , wherein said fibulin-5 and said VEGF are released slowly by degradation of said polymer.

5. An implantable device for treating a vascular disease or disorder comprising an intravascular prosthesis, wherein said device is coated with a substrate comprising endothelial cells that are genetically altered to express or over-express an inhibitor of smooth muscle cell proliferation and a growth factor for enhancing endothelial cell proliferation, wherein said inhibitor of smooth muscle cell proliferation is fibulin-5 polypeptide, and wherein said growth factor for enhancing endothelial cell proliferation is VEGF polypeptide.

6. The device of claim 5 , wherein said intravascular prosthesis is a stent.

7. The device of claim 5 , wherein said vascular disease is restenosis.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 3, 2006
From: FLUGELMAN, MOSHE Y.
To: MULTI-GENE VASCULAR SYSTEMS LTD. ("MGVS")
Reel/Frame 018153/0326 →
Continuity (4)
Continuation In Part 1016338700 · Jun 4, 2002
Continuation In Part 1016421900 · Jun 4, 2002
Continuation In Part 0962027700 · Jul 20, 2000
Related Publication 20060275338A1 · Dec 7, 2006